COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Rheumatoid Arthritis (DMARD) Intervention and UtilizationStudy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00116714
Recruitment Status : Completed
First Posted : July 1, 2005
Last Update Posted : May 6, 2011
Immunex Corporation
Wyeth is now a wholly owned subsidiary of Pfizer
Information provided by:

Brief Summary:
The Rheumatoid Arthritis DMARD Intervention and Utilization Study (RADIUS 1) is designed to systematically collect and document use patterns, effectiveness, and safety of DMARD treatments currently used in the management of rheumatoid arthritis (RA). It is anticipated that study data may help improve the quality of information upon which clinical decisions are based.

Condition or disease Intervention/treatment
Rheumatoid Arthritis Drug: DMARD

Layout table for study information
Study Type : Observational
Actual Enrollment : 4968 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Rheumatoid Arthritis Disease Modifying Anti-Rheumatic Drug (DMARD) Intervention and Utilization Study (RADIUS 1)
Study Start Date : October 2001
Actual Primary Completion Date : December 2007
Actual Study Completion Date : October 2008

Resource links provided by the National Library of Medicine

Group/Cohort Intervention/treatment
Observation Drug: DMARD
All subjects were required to initiate, add or change DMARD therapy at study entry.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Subjects with RA according to ACR criteria, and who are starting, adding or changing DMARD therapy, including biologics.

Inclusion Criteria:

  • Fulfillment of the 1987 American Rheumatism Association criteria for RA
  • Currently requiring a new DMARD (change or addition)

Exclusion Criteria:

  • Currently enrolled in a clinical trial with treatments or patient visits imposed by a protocol
  • Nursing or pregnant women
  • Patients with active infection

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00116714

Sponsors and Collaborators
Immunex Corporation
Wyeth is now a wholly owned subsidiary of Pfizer
Layout table for investigator information
Study Director: MD Amgen
Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Global Development Leader, Amgen Inc. Identifier: NCT00116714    
Other Study ID Numbers: 20021634
First Posted: July 1, 2005    Key Record Dates
Last Update Posted: May 6, 2011
Last Verified: May 2011
Keywords provided by Amgen:
rheumatoid arthritis
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases